Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback